Today: 29 June 2026
Browse Category

NASDAQ:HIMS 29 September 2025 - 2 June 2026

Hims Kicks Off $1.15 Billion Global Push; Shares Hold Back

Hims Kicks Off $1.15 Billion Global Push; Shares Hold Back

NEW YORK, June 2, 2026, 10:13 a.m. EDT Hims & Hers Health shares moved lower Tuesday morning after the company announced it wrapped up its buyout of Australia’s Eucalyptus. The telehealth firm called the deal part of a push for expansion outside the U.S. as changes keep coming to its American weight-loss business. Hims was down 0.9% at $27.52 in early trade after starting the session at $27.93 and hitting a high of $28.85.
2 June 2026
·
Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers. That’s suddenly important, with forecasts tightening up. Wall Street’s consensus sits around $617 million for first-quarter revenue, and EPS is pegged between 3 and 4 cents, according to public estimate trackers. Hims shares finished Friday’s regular session at $28.46, ticking up to $29.07 in after-hours trading.
11 May 2026
····
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Health surged 10.2% Friday to finish at $28.27, ahead of first-quarter earnings set to drop after Monday’s closing bell. Despite the pop, shares remain lower on the year. Investors are zeroed in on Monday as a clearer barometer for the telehealth firm’s shift into weight loss. Subscriber growth isn’t the only question hanging over Hims. What’s on investors’ minds: can the company move away from lower-cost compounded weight-loss meds and pivot to FDA-approved GLP-1 drugs—a group of diabetes and obesity treatments targeting appetite and blood sugar—without giving up the growth that’s made the stock one of healthcare’s wilder rides?
9 May 2026
···
Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot

Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot

Hims & Hers Health got a boost Friday, climbing about 9% to $30.70 after JPMorgan initiated coverage with an overweight rating and slapped on a $35 price target. The new call gives the telehealth firm a shot in the arm following heated back-and-forth over its weight-loss approach. This call takes on new weight as Hims looks to demonstrate its obesity segment can maintain momentum even as access to pharmacy-made versions of weight-loss drugs—which had fueled growth during recent shortages—wanes. GLP-1 drugs fall into a broader class used for diabetes and weight loss; they act like a natural gut hormone, steadying blood sugar and slowing stomach emptying, so people feel full longer.
24 April 2026
·
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment. Hims is making a significant pivot, stepping back from its more controversial compounded GLP-1 model—where pharmacies tailor-make drugs for individual patients—and instead moving toward branded, FDA-approved options. Back in March, the company announced it would stop marketing compounded GLP-1s, striking a deal with Novo Nordisk to add Ozempic and Wegovy to its platform.
21 April 2026
·····
Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Health jumped another 8.9% by 10:25 a.m. EDT on Monday, pushing its winning streak further. Omnicell and Privia Health only managed gains of less than 1%. Telehealth stocks like Hims & Hers remain in focus after Yahoo Finance highlighted the company’s 48.3% surge over the past week ahead of its earnings release set for May 11. This shift stands out, given the sector hasn’t shown widespread weakness. In recent healthcare-technology roundups, most of the group surpassed fourth-quarter revenue expectations, but recent analyses divided sharply over names like Hims, Privia, and Omnicell. StockStory noted that the four companies focused on hospitals and clinics beat revenue estimates by 1.8%. IndexBox, in a broader look published Friday, also found seven healthcare-tech firms exceeded estimates, singling out Hims & Hers and Privia for standout performance.
20 April 2026
····
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance. This surge traces back to a shift in Hims’ weight-loss strategy—not just a flash of momentum. The company locked in a new agreement with Novo Nordisk, settling their patent fight and putting FDA-approved Wegovy and Ozempic back in Hims’ lineup. As a result, Hims will largely drop compounded GLP-1 offerings, moving further from pharmacy-crafted alternatives in favor of the branded drugs that treat obesity and diabetes. Hims says Novo’s treatments hit the platform later this month.
12 March 2026
···
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares surged 5.9% to finish at $23.47 on Tuesday, building on a two-day rally that’s now hit roughly 49%. The telehealth firm had closed at $15.74 back on March 6, then soared to $22.16 at Monday’s close. During Tuesday’s session, the stock swung from $22.43 up to $26.03 before easing back to settle below its session peak, following news of a fresh distribution deal with Novo Nordisk. This rebound is notable: Hims was squeezed by regulators and Novo, but now there’s relief. Novo pulled its lawsuit, at least for now—it can bring it back if needed—removing a big cloud hanging over the company. The deal pushes Hims away from compounded GLP-1s—those pharmacy-mixed obesity treatments—and onto branded, FDA-approved drugs instead.
11 March 2026
··
Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Health shares jumped in premarket trading Monday, following a Bloomberg News report that Novo Nordisk plans to offer its weight-loss drugs via the telehealth platform. An announcement confirming the partnership could come as early as Monday, marking a reversal from last month’s patent dispute between the two firms. Why does it matter now? Hims could soon have a more direct path to FDA-approved supply, right as Washington sharpens its focus on compounded GLP-1 drugs—the diabetes meds also used for weight loss. Compounding, making customized versions for individual patients, took off during recent shortages, but the FDA is tightening the screws.
9 March 2026
···
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

New York, Feb 26, 2026, 08:43 EST — Premarket Hims & Hers Health shares nudged 0.3% higher ahead of Thursday’s open, building on Wednesday’s 2.3% advance. The telehealth firm wrapped up the last session at $15.82, after trading in a range from $15.06 to $16.46 during the day. On Tuesday, the stock had dropped to $13.74.
26 February 2026
···
Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

NEW YORK, Feb 8, 2026, 13:48 EST — Market closed Hims & Hers announced Saturday it’s discontinuing access to its compounded semaglutide pill—previously sold at $49 a month—after U.S. regulators threatened enforcement on off-brand weight-loss treatments. Shares in Hims dropped 15.9% Friday, closing at $19.36. https://www.reuters.com/legal/litigation/hims-hers-stop-offering-compounded-semaglutide-pill-after-fda-crackdown-2026-02-07/ https://finance.yahoo.com/quote/HIMS/history/
8 February 2026
··
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

New York, Feb 6, 2026, 08:45 EST — Premarket Shares of Hims & Hers Health dropped 3.8% to $23.48 in premarket trading on Friday. The slide came after FDA Commissioner Marty Makary warned the agency would act quickly against firms mass-marketing “illegal copycat drugs.” The stock had already fallen 3.8% on Thursday and plunged nearly 10% after hours, following Makary’s post on X stating, “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.” His comments came after Hims introduced a compounded version of Novo Nordisk’s Wegovy weight-loss medication.
6 February 2026
····
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

New York, February 5, 2026, 11:30 AM EST — Regular session Shares of Hims & Hers Health Inc swung sharply Thursday following the company’s announcement that it plans to offer a low-cost compounded version of Novo Nordisk’s new Wegovy weight-loss pill. Novo Nordisk promptly threatened legal action. The stock bounced back to $24.41 in late morning trading after earlier surging to $29.44.
5 February 2026
···
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results investors.hims.com. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims & Hers remains one of 2025’s most talked-about healthcare stocks – its fortunes tightly tied to both the telehealth boom and regulatory oversight. Sources: Recent filings and press releases investors.hims.com investors.hims.com; Reuters and AP news on regulatory actions reuters.com reuters.com reuters.com; analyst reports and SEC filings quiverquant.com marketbeat.com; and HIMS-sponsored studies/news investors.hims.com fox10tv.com.
29 September 2025
·

Stock Market Today

  • MINISO Group Stock Rises on New HK$2 Billion Buyback Plan
    June 29, 2026, 12:57 PM EDT. MINISO Group's board approved a HK$2 billion (Hong Kong dollars) share repurchase program starting June 2026, signaling confidence in its business outlook. The program allows repurchases through various methods based on market conditions without triggering mandatory general offers under Hong Kong's rules. The company views its shares as undervalued and aims to support shareholders while continuing business expansion. MINISO's stock rose 5.83% to $12.07 following the announcement. Management emphasized flexibility on timing, size, and price of buybacks. The move follows the near completion of its current 2024 buyback scheme.
Go toTop